Change in Sales Practices. The Parties acknowledge that during the term of this Agreement, Merck’s sales practices for the marketing and distribution of Product may change to the extent to which the calculation of the payment for royalties on Net Sales may become impractical or even impossible. In such event the Parties agree to meet and reasonably discuss in good faith new ways of compensating Company to the extent currently contemplated under Section 5.4.1.
Change in Sales Practices. The parties acknowledge that during the term of this Agreement, MERCK's sales practices for the marketing and distribution of Product may change to the extent to which the calculation of the payment for royalties on Net Sales may become impractical or even impossible. In such event the parties agree to meet and discuss in good faith new ways of compensating ISIS to the extent currently contemplated under Section 5.4.1.
Change in Sales Practices. The Parties acknowledge that during the term of this Agreement, Merck’s sales practices for [*] to the extent [*] may become [*]. In such event, at the request of Merck, the Parties [*] to the extent currently contemplated under this Section 5.4.
Change in Sales Practices. The Parties acknowledge that during the term of this Agreement, the royalty-paying Party's sales practices for the marketing and distribution of Therapeutic Collaboration Product may change to the extent to which the calculation of the payment for royalties on Net Sales may become impractical or even impossible. In such event the Parties agree to meet and discuss in good faith new ways of compensating the royalty-receiving Party to the extent currently contemplated under Section 5.2.1.
Change in Sales Practices. The Parties acknowledge that during the term of this Agreement, Merck may desire to change its sales practices for the marketing and distribution of Product to the extent to which the calculation of the payment for royalties on Net Sales may become impractical or even impossible. In such event the Parties agree to meet and discuss in good faith new ways of compensating Acumen to the extent currently contemplated under this Section 6.7 in a manner that does not disadvantage Acumen; [***] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
Change in Sales Practices. The Parties acknowledge that during the Term of this Agreement, MSD’s sales practices for the marketing and distribution of Licensed Product may change to the extent to which the calculation of the payment for royalties on Net Sales may become impractical or even impossible. In such event the Parties agree to meet and reasonably discuss new ways of compensating Company to the extent currently contemplated under Section 5.5.1. *** Certain information, as identified by [***], has been excluded from this agreement because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
Change in Sales Practices. The Parties acknowledge that during the term ------------------------- of this Agreement, Vical's sales practices for the marketing and distribution of Licensed Product may change to the extent to which the calculation of the payment for royalties on Net Sales may become impractical or even impossible. In such event the Parties agree to meet and discuss in good faith new ways of compensating CytRx to the extent currently contemplated under Section 4.1
Change in Sales Practices. The Parties acknowledge that during the Agreement Term, a Royalty Payor's sales practices for the marketing and distribution of an Ophthalmic Product may change to the extent to which the calculation of the payment for royalties on Net Sales may become impractical or even impossible. In such event the Parties agree to meet and discuss in good faith new ways of compensating the Royalty Recipient to the extent currently contemplated under this Section 8.3.
Change in Sales Practices. The Parties acknowledge that during the term of this Agreement, [†].
Change in Sales Practices. The Parties acknowledge that during the Agreement Term, a Royalty Payor's sales practices for the marketing and distribution of a [**] Product or an RNAi Therapeutic Product may change to the extent to which the calculation of the payment for royalties on Net Sales may become impractical or even impossible. In such event the Parties agree to meet and discuss in good faith new ways of compensating the Royalty Recipient to the extent currently contemplated under this Section 9.4.
